Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNION Therapeutics A\/S Receives FDA Approval for IND of Oral Next-Gen PDE4-Inhibitor for investigation in Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Union Therapeutics"},{"company":"Union Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"$267.0 million","upfrontCash":"$20.0 million","newsHeadline":"UNION therapeutics and Innovent Biologics Enter Into Strategic Collaboration and License Agreement for Orismilast, a Next-Generation PDE4 Inhibitor for Inflammatory Dermatology Conditions","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Union Therapeutics"},{"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNION therapeutics Announces Enrollment of the First Patient in ADESOS Phase 2b Study of Orismilast MR Tablet in Patients With Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Union Therapeutics"},{"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Union Therapeutics Presents New Data on Orismilast at the 31st EADV Congress Supporting Orismilast\u2019s Potential as a First-in-class or Best-in-class Treatment for Certain Immunological Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Union Therapeutics"},{"company":"Leo Pharma","sponsor":"UNION therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UNION Therapeutics Announces Acquisition of PDE4i Compound Class from LEO Pharma with Oral Lead Candidate (orismilast) in Phase 2","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Leo Pharma"},{"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Gets U.S. FDA Fast Track Designation for delgocitinib Cream for the Treatment of Adults With Moderate-to-severe Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Leo Pharma"},{"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Reports Results of Phase 2b Dose-Finding Study with Delgocitinib cream in Patients with Mild-to-Severe Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Leo Pharma"},{"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Initiates a Phase 2b Dose-Ranging Clinical Trial With an Oral H4R Antagonist in Adult Patients With Moderate-to-Severe Atopic Dermatitis (AD)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Leo Pharma"}]

Union Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Union Therapeutics Presents New Data on Orismilast at the 31st EADV Congress Supporting Orismilast’s Potential as a First-in-class or Best-in-class Treatment for Certain ...

Details:

Preclinical data demonstrated that UNI50001 (orismilast) is potent inhibitor of phosphodiesterase type-4 (PDE4), and that orismilast more selectively inhibit PDE4B and PDE4D subtypes which are considered more relevant in treatment of immunological diseases.

Lead Product(s): Orismilast

Therapeutic Area: Dermatology Product Name: UNI50001

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 09, 2022

ASK
US

Upload
your Pipeline Activity

Union Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

UNION therapeutics Announces Enrollment of the First Patient in ADESOS Phase 2b Study of Orismilast MR Tablet in Patients With Atopic Dermatitis

Details:

UNION is developing orismilast, which is a potent next-generation phosphodiesterase type-4 (PDE4) inhibitor operating early in the inflammation cascade to induce a broad spectrum of downstream anti-inflammatory effects.

Lead Product(s): Orismilast

Therapeutic Area: Dermatology Product Name: UNI50001

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 04, 2022

ASK
US

Upload
your Pipeline Activity

Leo Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

LEO Pharma Initiates a Phase 2b Dose-Ranging Clinical Trial With an Oral H4R Antagonist in Adult Patients With Moderate-to-Severe Atopic Dermatitis (AD)

Details:

The primary objective for the randomized, triple-blind, placebo-controlled, multi-center Phase 2b dose-ranging clinical trial is to evaluate the efficacy of LEO 152020 compared with placebo in the treatment of adults with moderate-to-severe AD.

Lead Product(s): LEO 152020

Therapeutic Area: Dermatology Product Name: LEO 152020

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 14, 2021

ASK
US

Upload
your Pipeline Activity

Union Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

UNION therapeutics and Innovent Biologics Enter Into Strategic Collaboration and License Agreement for Orismilast, a Next-Generation PDE4 Inhibitor for Inflammatory Dermato...

Details:

Under the terms of the agreement, UNION grants Innovent an exclusive license to research, develop and commercialize orismilast in China, including participating in and recruiting Chinese patients for potential future global studies of orismilast.

Lead Product(s): Orismilast

Therapeutic Area: Dermatology Product Name: UNI50001

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Innovent Biologics

Deal Size: $267.0 million Upfront Cash: $20.0 million

Deal Type: Collaboration September 28, 2021

ASK
US

Upload
your Pipeline Activity

Union Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

UNION Therapeutics A/S Receives FDA Approval for IND of Oral Next-Gen PDE4-Inhibitor for investigation in Plaque Psoriasis

Details:

Orismilast is a next generation oral PDE4-inhibitor with an improved therapeutic window compared to other PDE4-inhibitors. Oral orismilast (UNI50001) has demonstrated proof of concept in patients living with plaque psoriasis and indicated "best-in-class" potential.

Lead Product(s): Orismilast

Therapeutic Area: Dermatology Product Name: UNI50001

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 07, 2021

ASK
US

Upload
your Pipeline Activity

Leo Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

LEO Pharma Reports Results of Phase 2b Dose-Finding Study with Delgocitinib cream in Patients with Mild-to-Severe Chronic Hand Eczema

Details:

Delgocitinib inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases. delgocitinib cream demonstrated a statistically significant dose-response relationship in the trial.

Lead Product(s): Delgocitinib

Therapeutic Area: Dermatology Product Name: LEO 124249

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Japan Tobacco Inc

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 29, 2020

ASK
US

Upload
your Pipeline Activity

Leo Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

LEO Gets U.S. FDA Fast Track Designation for delgocitinib Cream for the Treatment of Adults With Moderate-to-severe Chronic Hand Eczema

Details:

Delgocitinib inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.

Lead Product(s): Delgocitinib

Therapeutic Area: Dermatology Product Name: LEO 124249

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Japan Tobacco Inc

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 04, 2020

ASK
US

Upload
your Pipeline Activity

Leo Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

UNION Therapeutics Announces Acquisition of PDE4i Compound Class from LEO Pharma with Oral Lead Candidate (orismilast) in Phase 2

Details:

LEO Pharma has been developing candidates from this series from discovery into Phase 2 in psoriasis (orismilast, oral) and atopic dermatitis (orismilast, topical) and in both indications demonstrated superior effect over placebo.

Lead Product(s): Orismilast

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: UNION therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition July 21, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY